The Federal and Provincial Governments, along with Medtronic and GE Healthcare, announced a $40M+ multi-partner funding agreement for REFINE ICD, a clinical trial to be led globally at the Libin Cardiovascular Institute of Alberta (LCIA) by Dr. Derek Exner. The trial, which will have 75 sites and screen 10K subjects across North America, Europe and Japan, seeks to assess a novel method devised by Dr. Exner to predict the likelihood of sudden cardiac arrest (the cause of up to 50K deaths in Canada and 3M-5M globally per year) in individuals who have already had a heart attack. Subjects fitting the criteria will be randomized for receiving an implantable cardioverter defibrillator (ICD) or for current treatment options.
Dr. Exner, Professor of Cardiac Sciences at UCalgary, is currently the Medical Director of Cardiac Pacing and Electrophysiology at the Libin Cardiovascular Institute of Alberta. His work at the Institute builds on a 30+ year history of the LCIA being at the global forefront of cardiac electrophysiology research.
Government press release – Alberta researchers get to the heart of cardiac research
Click the following images for a sample of TV, Radio and Print coverage of this story: